Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2002

View Archived Issues

Pharming and GTC enter crosslicense agreement

Schering AG and Neurosciences Victoria sign neuroscience research collaboration

Pharmacopeia identifies lead series of compounds in Organon collaboration

Snapshots on thiazolidinediones at ENDO 2002

Novel antiplatelet agent discovered and characterized at Yamanouchi

Ro-25-4020: mechanism underlying enhanced anticancer properties compared to 1,25(OH)2D3

ACAT inhibitor with promising hypocholesterolemic effects under investigation at Sumitomo

Dual alpha/beta-adrenoceptor blocker and vasodilator characterized by Chinese group

The lipid-lowering effects of a combination of raloxifene and simvastatin

New oxytocin antagonists reported by Mitsubishi Pharma

Almirall Prodesfarma claims novel antihistaminic compounds

Adenovirus-mediated Apoptin gene transfer specifically kills tumor cells

Novel 5-HT2C agonists for use in obesity and psychiatric disorders

TPP-II inhibitors in early development at Janssen

Researchers at Allergan identify inhibitors of P-450RAI

Merck presents new alpha1A-adrenoceptor antagonists for BPH

Inhibitors of gamma-secretase in development at Merck & Co.

Nonsteroidal SERM with antiestrogenic effects in breast cancer cells, little uterotrophic liability

CPMP issues positive opinion reaffirming favorable risk/benefit profile of Reductil/Meridia

Noven files MethyPatch NDA for ADHD

Esperion initiates phase II study of ETC-588 in vascular disease

Calcimimetic AMG-073 may improve outcomes in patients with ESRD

Periostat receives final marketing approvals in Portugal and The Netherlands

Tariquidar enters phase III for multidrug-resistant NSCLC

Phase I/II follow-up data for GVAX lung cancer vaccine

Zevalin European launch delayed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...